References
- Hutzelmann J, Owens S, Shedden A, et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol 1998;82:1249-53
- COSOPT [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., 2006
- Nii H, Ikeda H, Okada K, et al. Circadian change of adenylate cyclase activity in rabbit ciliary processes. Curr Eye Res 2001;23:248-55
- Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230-8
- Azarga [package insert]. Puurs, Belgium: Alcon Laboratories, Inc., 2008
- Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology 2008;115:1728-34
- Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2009;18:293-300
- Vold SD, Evans RM, Stewart RH, et al. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharm Ther 2008;24:601-5
- Mundorf TK, Rauchman SH, Williams RD, et al. A patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2008;2:623-8
- Siesky B, Harris A, Cantor LB, et al. A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma. Br J Ophthalmol 2008;92:500-4
- Martínez A, Sanchez-Salorio M. Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma. Acta Ophthalmol 2010;88:541-52
- Harris A, Siesky B, Shoshani Y, et al. Predictors for visual field progression. Acta Ophthalmol. 2010;88:504-5
- Holló G. Brinzolamide/timolol fixed combination for open-angle glaucoma and ocular hypertension. Expert Rev Ophthalmol 2009;4:129-33
- Chan K, Testa M, McCluskey P. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%. J Ocul Pharmacol Ther 2007;23:372-6
- Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000;22:1204-12
- Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8
- Silva LR, de Paula JS, Rocha EM, et al. Factors related to glaucoma treatment compliance: patients' opinions from a University Hospital. Arq Bras Oftalmol 2010;73:116-19
- Bloch S, Rosenthal AR, Friedman L, et al. Patient compliance in glaucoma. Br J Ophthalmol 1977;61:531-4